In Segment C, members will acquire ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment until condition progression or perhaps the participants are not able to tolerate the study drugs. Ubiquitin-associated proteins that regulate The steadiness of essential super enhancer-mediated proteins have https://abbv-744-combination-ther68013.jts-blog.com/31222498/a-simple-key-for-abbv-744-brd4-inhibition-in-cancer-cell-lines-unveiled